Jim Cramer’s Latest Stock Moves: Top 10 Calls

4. Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Number of Hedge Funds Investors: 62

Jim Cramer said in response to a question during a recent program on CNBC that he’d recommend investors own Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

“I will tell you this for Regeneron, I want you to own it. I think it’s doing better than people realize. That is a good stock, and I’m going to give it too. I still like Bristol Myers.”

Amalthea Fund stated the following regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q3 2024 investor letter:

“Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – the biggest loser in the book by absolute dollars. Regeneron is a large position for us. We wrote the position up in June 2021 letter. The stock has almost doubled since the original write-up, but it is down on the month. Allow some time for an explanation There are two ways of looking at Regeneron. The sum-of-the-parts way and the platform way.

Regeneron has 11 approved drugs but two comprise most of the cash flows. The two are Eylea and Dupixent.

Eylea is a VEGF drug that is injected into patients’ eyes and stops macular degeneration (the main cause of blindness in old people). The drug stops capillaries growing in the retina…” (Click here to read the full text)